• What is the RTDC?
• Learn More
• Take Action
• Information for Physicians
• Information for Investigators
• News & Events
• Participating Clinical Centers

• Contact Information

Duke Hemostasis and Thrombosis Center

Duke Hemostasis and Thrombosis Center

Contact Information:

Clinical Trials:

5801: The Incidence of Thromboembolic Events in Patients with Antibodies to Heparin-PF4 after Cardiac Bypass

5806: Genetics of antiphospholipid antibody syndrome (APS)

About Us:

The Duke Hemostasis & Thrombosis Center is a multidisciplinary program devoted to improving the care of patients with bleeding and clotting disorders through innovative basic and clinical research efforts. The Center was formed in 2001, when it was selected by the Centers for Disease Control & Prevention to be one of eight pilot Hemostasis & Thrombosis Centers in the United States . Leadership of the program includes faculty in Hematology, Maternal-Fetal Medicine, Pediatric Hematology, and Cardiology. Ongoing clinical research trials are investigating the optimal 'dose' of platelets for replacement therapy, the role of inherited hypercoagulable states in intrauterine growth restriction, and therapeutic strategies for patients with end-stage renal disease and recurrent vascular access occlusions.

The Duke Clinical Coagulation Laboratory is a national coagulation reference laboratory that provides the medical community with both routine and sophisticated procedures to aid in the diagnosis and treatment of patients with coagulation disorders. The Coagulation Laboratory is also an integral part of the healthcare team at Duke University Medical Center , and works closely with the inpatient and outpatient consult teams. The Coagulation Laboratory is one of the founding members of NASCOLA (North American Specialized Coagulation Laboratories). Dr. Ortel has been the Medical Director of the Coagulation Laboratory since 1995. Dr. Jogin Wu, the Associate Director of the Coagulation Laboratory since 2000, brings a strong background in basic research in coagulation and extensive managerial experiences in new technology development, biochemistry and immunology. Current technologies in use in the Coagulation Laboratory include photo-optical and mechanical clot-based assays, chromogenic assays, platelet aggregometry, ELISA and other immunoassays, and molecular diagnostic testing. This laboratory works to identify and develop new testing methodologies to improve the diagnosis and management of patients with disorders of hemostasis.

The Duke Center for Human Genetics is central to Duke's ongoing efforts to elucidate the underlying genetic causes of complex diseases. The Center for Human Genetics (CHG) was established in 1996 and uses family histories, sophisticated molecular analyses, and statistical genetics to reveal the genetic origin of a wide array of disorders, including the muscular dystrophies, Alzheimer's disease and cardiovascular diseases.

The mission of the Center for Human Genetics is the ongoing discovery of the genetic and epidemiological basis of human disease--both rare, single-gene disorders and common conditions like heart disease, diabetes, and cancer, which are caused by the interaction of multiple genes and, often, environmental factors. Using sophisticated and proven methodology long employed at Duke for the study of Alzheimer disease, multiple sclerosis, and other neurological disorders, Center researchers continue to broaden the understanding of human genetics through research initiatives that will foster the development of new therapies for genetic disease. The center examines the genetic origins of a broad array of disorders through detailed family histories, state-of-the-art molecular analyses, and statistical genetics. It provides expertise in the disciplines of molecular epidemiology, genetic epidemiology, bioinformatics, positional cloning, gene mapping, and genome technology development and seeks to broaden the understanding of human genetics and to foster the development of new therapies for genetic disease.

The Center for Human Genetics is made up of two core facilities. The Genomics Research Laboratory Core is a world-renowned resource for DNA banking, high throughput genotyping and mutation analysis. Applying data from the Human Genome Project this core provides the molecular and laboratory support for the Center for Human Genetics' multiple ongoing research projects in disease etiology. The Family Studies and Bioinformatics Core is a centralized resource for all aspects of gene identification that includes the Duke-designed, licensed, and internationally acclaimed PEDIGENE® data management system. By storing and integrating data from all phases of a genetic study, PEDIGENE ® greatly facilitates data analysis and has already played a key role in localizing or mapping more than 50 disease genes. Bioinformatics initiatives at the Center for Human Genetics are mining the wealth of available genomic data and applying it to research in human disease.

The Duke Clinical Research Institute (DCRI) is the world's largest academic clinical research organization. Its mission is to develop and share knowledge that improves the care of patients around the world through innovative clinical research. As an academic research organization, the DCRI's role is to provide leadership in the design, execution, and analysis of innovative clinical investigations, and to ensure that these studies are conducted according to the highest methodological and regulatory standards. The DCRI embraces the concept that close integration of clinical, biostatistical, informatics, economics, behavioral, data management, and project management expertise is essential for successful clinical research. The DCRI consists of over 850 individuals, including 150 physician-investigators, 15 PhD faculty biostatisticians, 10 health services researchers and psychologists, 30 project leaders, 42 non-faculty biostatisticians, 11 statistical programmers, and large data management and site manage­ment groups. Approximately 175 personnel are devoted to infrastructure support, which includes proposals development, regulatory affairs, information technology, quality assurance, finance, human resources, and communications. This multidisciplinary approach ensures that the breadth and quality of support needed for all phases of the project, from protocol development to project reporting, is readily available. DCRI has earned an international reputation as a leader in cardiovascular databases and clinical trials, and over the past eight years, it has developed research programs in every major area of medicine and surgery. Its faculty and staff are now providing intellectual leadership and coordination for more than 100 projects, including clinical trials, outcome studies, and registries, involving more than 500,000 patients across nearly 3,500 clinical research sites in more than 58 countries.

Useful Links:

Duke Hemostasis and Thrombosis Center

The Duke Center for Human Genetics

Duke Clinical Coagulation Laboratory

Duke Clinical Research Institute

Publications:

Hansen KE, Kong DF, Moore KD, Ortel TL. Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol. 2001 Sep;28(9):2018-24.Abstract

Goel N, Ortel TL, Bali D, Anderson JP, Gourley IS, Smith H, Morris CA, DeSimone M, Branch DW, Ford P, Berdeaux D, Roubey RA, Kostyu DD, Kingsmore SF, Thiel T, Amos C, Seldin MF. Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance. Arthritis Rheum. 1999 Feb;42(2):318-27.   Abstract

Erkan D, Ortel TL, Lockshin MD. Warfarin in antiphospholipid syndrome - time to explore new horizons. J Rheumatol. 2005 Feb;32(2):208-12.   Abstract

Rand JH, Wu XX, Lapinski R, van Heerde WL, Reutelingsperger CP, Chen PP, Ortel TL. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood. 2004 Nov 1;104(9):2783-90.   Abstract

O'shea SI, Lawson JH, Reddan D, Murphy M, Ortel TL. Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg. 2003 Sep;38(3):541-8.   Abstract

Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D, Sullenger BA. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature. 2002 Sep 5;419(6902):90-4.   Abstract